CureVac founder back at the helm; Merck extends immunomodulatory drug discovery program with Sutro
→ Daniel Menichella, the CEO of CureVac and the face of its recent endeavors to develop an mRNA vaccine against Covid-19, is stepping down. Founder Ingmar Hoerr is back in charge; the transition happens just days after Menichella attended the high-profile White House coronavirus R&D meeting alongside other biopharma execs. While Hoerr thanked Menichella for “his leadership having built a terrific global team” and extolled the pipeline that he left behind, no reason was given for the sudden departure.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.